YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
In a landmark move beginning July 1, 2026, Medicare, under its "GLP-1 Bridge" demonstration program, is set to provide eligible U.S. seniors with access to popular weight-loss medications like Wegovy, Zepbound, and Foundayo for a copay of…
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since…
The weight loss drug market has evolved into one of the most explosive, flourishing segments of the global healthcare industry, driven by an unprecedented surge in demand for glucagon-like peptide-1 (GLP-1) receptor agonists. At the center…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare companies delivered strong earnings this week, with 18 out of 20 companies beating EPS estimates and 15 to…
[Magnifying Glass On Top Of Bar Chart] DNY59 Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over-year EPS growth. All 22 companies recorded year-over-year revenue in…
Photo by Clay Banks via Unsplash GLP-1 investors haven’t gained as much as expected from others’ losses. Since the FDA approved Wegovy, also known as semaglutide, as an injectactable treatment to help people manage their weight, several ex…
In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETF…